Phenacetin
NERVOUS SYSTEM
Also known as: acetophenetidin, acetophenetidine, acetophenetin, acetphenetidin, phenacetine, phenazetin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Phenacetin is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1887. DrugCentral lists 1 molecular target, including PTGS1.
- Molecular targets: PTGS1 (1 listed in DrugCentral).
- ATC code: N02BE03 (Anilides).
- Molecular formula: C10H13NO2; molecular weight 179.22 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Contraindications (47)
- Acute erosive gastritis
- Acute exacerbation of asthma
- Acute nephropathy
- Agoraphobia
- Alcoholism
- Anemia
- Anemia due to enzyme deficiency
- Breastfeeding (mother)
- Chronic obstructive lung disease
- Conduction disorder of the heart
- Depressive disorder
- Disease of liver
- Factor II deficiency
- Gastrointestinal hemorrhage
- Gastrointestinal ulcer
- Gout
- Hemophilia
- Hepatic coma
- Hepatic encephalopathy
- Hepatic failure
- Hyperactive behavior
- Hyperammonemia
- Hypertensive disorder
- Impaired renal function disorder
- Insomnia
- Kidney disease
- Myocardial infarction in recovery phase
- Myocardial ischemia
- Nasal polyp
- Necrotizing enterocolitis in fetus OR newborn
- + 17 more
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | PTGS1 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1887-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02BE03 | NERVOUS SYSTEM › ANALGESICS › OTHER ANALGESICS AND ANTIPYRETICS › Anilides |
N02BE53 | NERVOUS SYSTEM › ANALGESICS › OTHER ANALGESICS AND ANTIPYRETICS › Anilides |
N02BE73 | NERVOUS SYSTEM › ANALGESICS › OTHER ANALGESICS AND ANTIPYRETICS › Anilides |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxicity to various agents | 248.6 |
| Adulterated product | 164.8 |
| Intentional product misuse | 117.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Phenacetin is on its molecule page.
| Molecular formula | C10H13NO2 |
|---|---|
| Molecular weight | 179.22 g/mol |
| CAS number | 62-44-2 |
| InChIKey | CPJSUEIXXCENMM-UHFFFAOYSA-N |
| PubChem CID | 4754 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
How does Phenacetin work?
Its molecular targets in DrugCentral include PTGS1.
When was Phenacetin first approved?
Phenacetin was first approved by the YEAR INTRODUCED in 1887.
What is the chemical formula of Phenacetin?
Phenacetin has the molecular formula C10H13NO2 and a molecular weight of 179.22 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2115 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL16073 — compound record and bioactivity
- PubChem CID 4754 — chemical identifiers
- DrugBank DB03783 — drug record
- FDA UNII ER0CTH01H9 — substance identity
- UniProt P23219 (PTGS1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.